Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Explore the Innovation Trends Shaping Tomorrow’s Investment Landscape (click to learn more) Sekur Private Data Advances Defense-Grade Secure Communications Platform (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Enanta Pharmaceuticals Inc ENTA

Healthcare Biotechnology
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of... see more

Current News (NDAQ:ENTA)

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

Business Wire 2 days ago

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

Business Wire 10 days ago

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

Business Wire April 13, 2026

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026

Business Wire April 7, 2026

Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)

Business Wire March 30, 2026

Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference

Business Wire March 3, 2026

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting

Business Wire February 10, 2026

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

Business Wire February 9, 2026

Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook

Business Wire January 8, 2026
View More News ››

Opinion & Analysis (NDAQ:ENTA)

Biopharma Starts 'Key Catalyst Period,' H2/19, with Clinical Trial in New Indication

Streetwise Reports July 11, 2019

Biotech Reports 'Eye-Catching, Topline Results' from RSV Vaccine Study

Streetwise Reports June 21, 2019

U.S. Biopharma's 'Biggest Stock Moving Event' Imminent

Streetwise Reports May 27, 2019
View More Opinion ››

Bullboard Posts (NDAQ:ENTA)

RE:$MYNZ

No position
Iseneschal - June 11, 2025

RE:ENTA ....mid morning NR....Good News also !

Possible breakout if $8.90 get breeched GLTA
Iseneschal - June 11, 2025

ENTA ....mid morning NR....Good News also !

$8.30 ish
Iseneschal - June 11, 2025

Using technical analysis for this stock.

This is a good companyand it is time to get on board with it.
coolfooldumbguy - February 13, 2025
View more Bullboard ››

Calima Energy Ltd (EM)

Calima Energy Ltd (EM)

Calima Energy Limited invests in oil and gas exploration and production projects in Canada and internationally. The company ...
View More »

Podcasts